Compare ADPT & RH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | RH |
|---|---|---|
| Founded | 2009 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2019 | 2011 |
| Metric | ADPT | RH |
|---|---|---|
| Price | $15.14 | $156.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 14 |
| Target Price | $17.78 | ★ $167.00 |
| AVG Volume (30 Days) | ★ 1.7M | 762.9K |
| Earning Date | 05-05-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.89 | ★ 74.31 |
| EPS | N/A | ★ 6.31 |
| Revenue | $276,976,000.00 | ★ $1,193,046,000.00 |
| Revenue This Year | $3.98 | $8.39 |
| Revenue Next Year | $22.72 | $9.44 |
| P/E Ratio | ★ N/A | $23.67 |
| Revenue Growth | ★ 54.77 | 24.52 |
| 52 Week Low | $9.78 | $106.30 |
| 52 Week High | $20.76 | $256.78 |
| Indicator | ADPT | RH |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 70.39 |
| Support Level | $14.87 | $151.71 |
| Resistance Level | $15.27 | $242.33 |
| Average True Range (ATR) | 0.64 | 8.67 |
| MACD | 0.23 | 3.00 |
| Stochastic Oscillator | 88.33 | 95.73 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and is growing the presence of its hospitality business with 25 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.